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Mycobacterium tuberculosis (Mtb) kills more people worldwide than any single infectious
pathogen, yet the only vaccine licensed against tuberculosis, Bacille Calmette Guerin
(BCG) is approaching its centenary. Two recent advances in clinical tuberculosis vaccine
development have invigorated the field. BCG revaccination of interferon-gamma release
assay (IGRA) negative adolescents provided 45% protection against sustained Mtb
infection defined by IGRA conversion; and the protein-subunit vaccine M72/AS01E
provided 50% protection against progression from Mtb infection to tuberculosis disease
in IGRA-positive adults. These findings provide encouraging evidence for pre-exposure
and post-exposure approaches to vaccination against tuberculosis, both of which may
be necessary to rapidly interrupt the cycle of Mtb transmission and sustain long-term
impact on global tuberculosis control. New trials are needed to demonstrate efficacy of
M72/AS01E with greater precision, in a wider age range, in diverse epidemic settings,
and in populations that include Mtb-uninfected and HIV-infected persons. Modeling the
impact of mass campaigns with M72/AS01E and other fast-follower vaccine candidates
will be crucial to make the use case and demonstrate public health value for TB endemic
countries. The size and scope of the next generation of efficacy trials, and the need to
expand and accelerate the existing clinical development pipeline, will require public and
private consortium funding and concerted political will.
Keywords: vaccine, development, Bacille Calmette Guerin, Mycobacterium tuberculosis, tuberculosis
INTRODUCTION
The global tuberculosis (TB) epidemic is a chronic humanitarian tragedy that continues unchecked
despite, or perhaps because of the fact that the only vaccine licensed against TB, the world’s leading
cause of death by an infectious pathogen (World Health Organizataion [WHO], 2018c), has been
used for almost a century. Infant Bacille Calmette Guerin (BCG) vaccination provides consistent
protection against the most severe forms of childhood TB, such as miliary and meningeal TB disease
(Mangtani et al., 2014). However, with the possible exception of low TB incidence settings (Aronson
et al., 2004; Barreto et al., 2005; Abubakar et al., 2013; Mangtani et al., 2017), BCG efficacy wanes in
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adolescence (Sterne et al., 1998). BCG vaccination offers little
or no protection against adult-type pulmonary TB (Mangtani
et al., 2014), which is responsible for the transmission of
Mycobacterium tuberculosis (Mtb) to susceptible people. It is
thus not surprising that despite universal infant BCG vaccination
in TB-endemic countries, an estimated 10 million people
developed TB and 1.6 million people died from the disease
worldwide in 2017, including 300,000 HIV/TB co-infected
patients (World Health Organizataion [WHO], 2018c). Given
the scale of the global TB epidemic and the slow pace of TB
control efforts, it is clear that a new and more effective TB
vaccine is needed to achieve World Health Organization (WHO)
End TB Strategy targets by reducing TB deaths by 95% and
new cases of TB by 90% by 2035 (Abu-Raddad et al., 2009;
Uplekar et al., 2015).
TARGET POPULATIONS FOR A NEW
TUBERCULOSIS VACCINE
The WHO has developed Preferred Product Characteristics
(PPC) (Schrager et al., 2018) and identified two target populations
for new TB vaccines: (1) adolescents and adults; and (2) infants.
It is recognized that although a new infant TB vaccine that offers
more effective durable protection than BCG would be desirable,
any new infant vaccination strategy would require many years to
demonstrate major impact on the epidemic (Knight et al., 2014).
For example, mass vaccination of adults using a new TB vaccine
with only 40% efficacy would achieve the same initial reduction
in TB incidence 20 years earlier than an infant vaccine with 80%
efficacy and lifelong protection (Knight et al., 2014). Developing
a new vaccine for use in mass campaigns to prevent pulmonary
TB among adolescents and adults will be necessary to interrupt
the cycle of Mtb transmission in the short- and medium-term
(Knight et al., 2014), whereas some combination of infant and
adolescent/adult vaccination approaches would likely be optimal
to sustain long-term TB control (Harris et al., 2016).
Approximately 23% of the global population is thought to
be infected with Mtb (Houben and Dodd, 2016), forming a
large reservoir of future TB cases that includes both drug-
sensitive (DS) and drug-resistant (DR) TB strains. However,
it is recognized that individuals with long-standing quiescent
Mtb infection that has historically been termed “latent” are
relatively protected, with 79% lower risk against progression
to TB disease in the face of reinfection than uninfected
people (Andrews et al., 2012). It has been proposed that
many people thought to have long-standing “latent” infection,
although sensitized to Mtb, are predominantly uninfected
and at much lower risk of subsequent disease (Behr et al.,
2018). Although only 10–15% of Mtb-infected people will
progress to TB disease in their lifetime, risk of progression
is most likely in the 1–2 years immediately after initial Mtb
infection (Behr et al., 2018). Therefore, the uninfected 77% of
the global population (approximately 6 billion people) form
a large pool of susceptibles amongst whom, once exposed,
those who become newly infected would be at highest risk
of developing TB disease. This paradox, the large number of
chronically Mtb-infected people at long-term low risk, and
the much smaller number of recently infected and “yet-to-be-
infected” people at short-term high risk, poses a major challenge
for TB vaccine development in identifying who should be
vaccinated and when. That challenge is compounded by our
inability to precisely define the time of Mtb exposure and the
lack of direct tests for infection. Current tests for immune
sensitization to Mtb, such as the interferon-gamma release
assay (IGRA), cannot differentiate between distant and recent
infection. Therefore, those recently Mtb-infected individuals at
highest risk of progression to TB, estimated at 0.8% of the global
population (55 million people), largely remain hidden among
the much larger pool of 1.7 billion “latently” infected people
(Houben and Dodd, 2016).
How can a new TB vaccination strategy offer protection
both to “most of those at risk,” as well as “those most at risk,”
given current limitations of predictive and diagnostic tests?
Large cohort studies have identified proteomic (Penn-Nicholson
et al., 2019) and transcriptomic (Suliman et al., 2018b; Zak
et al., 2016; Warsinske et al., 2018) host blood biomarkers
and high IGRA conversion threshold values (interferon-gamma
>4.0 IU/mL) (Winje et al., 2018; Andrews et al., 2017) that predict
which infected individuals have highest risk of progression to
TB disease. However, it is highly unlikely that pre-vaccination
screening, even to identify IGRA-positive people, would be
feasible in high TB incidence developing countries with limited
resources and constrained health system capacity.
It is likely that future TB vaccination programs would use
age-targeting to tailor routine vaccination schedules and mass
campaigns for either Mtb-uninfected infants, children, and pre-
adolescents in a pre-exposure strategy, or for Mtb-infected
adolescents and adults in a post-exposure strategy, to maximize
cost-effectiveness (Harris et al., 2016). However, the feasibility
and efficiency of age-targeted vaccination would likely differ by
country, depending on age-specific prevalence of Mtb infection
and TB disease, which varies widely even in high TB burden
countries. For example, prevalence of Mtb infection defined
by positive IGRA in China was 3% in adolescents, rising to
33% in older adults, consistent with the epidemiology of an
aging TB epidemic (Gao et al., 2015). It follows that a post-
exposure vaccination campaign for Mtb-infected people in China
should target primarily older adults, an approach which has
the maximum modeled population-level impact on the Chinese
epidemic (Harris et al., 2019). By contrast, in South Africa,
49% of adolescents and 56% of adults were IGRA-positive
(Bunyasi et al., 2019; Mahomed et al., 2006), consistent with
a high rate of ongoing Mtb transmission to younger people.
Notably, although a post-exposure vaccination campaign among
South African adolescents would include a greater proportion
of IGRA-positive individuals than in China (Gao et al., 2015;
Bunyasi et al., 2019), half of adolescent vaccinees would still
be Mtb-uninfected. Lower prevalence rates of Mtb infection
among adolescents in e.g., Kenya (32%) (Nduba et al., 2019) and
Uganda (16%) (Mumpe-Mwanja et al., 2015), would favor a pre-
exposure rather than a post-exposure approach for adolescents
in these and other countries with lower Mtb transmission rates
(Gao et al., 2015). This distinction is important, because TB
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FIGURE 1 | Target populations for new TB vaccines include Mtb-uninfected
(pre-exposure) and Mtb-infected, TB diseased, and treated individuals
(post-exposure). Risk of Mtb infection and progression to TB disease
increases with age (time at risk). Pre-exposure strategies for TB vaccination of
Mtb-uninfected individuals include both prevention of infection (POI) and
prevention of disease (POD). Post-exposure strategies include vaccination of
Mtb-infected individuals to prevent progression to TB disease (POD);
vaccination of TB patients to improve treatment outcomes (therapeutic); and
vaccination of treated TB patients to prevent recurrent disease (POR).
Therapeutic vaccination might also confer POR benefit.
disease incidence rises sharply from 15 to 25 years of age in
endemic countries (Hermans et al., 2015). The benefit of delay
in vaccination until adulthood to allow for higher prevalence of
Mtb infection in a post-exposure vaccination strategy, would be
counter-balanced by missed opportunities to prevent TB cases
among younger people.
PRE-EXPOSURE APPROACHES TO
INFANT VACCINATION
The principle that an individual should be vaccinated before,
rather than during or after the period of highest risk for disease
(Behr et al., 2018), suggests that pre-exposure vaccination of Mtb-
uninfected people might eventually have greater population-level
impact than post-exposure vaccination of Mtb-infected people.
This approach hinges on the key assumptions that pre-exposure
vaccination is feasible and, crucially, offers durable long-term
protection lasting decades (Schrager et al., 2018) Figure 1.
Can pre-exposure vaccination of Mtb-uninfected humans
protect against subsequent TB disease? The clearest evidence
is the example of BCG vaccination for newborn infants, the
classical Mtb-unexposed and Mtb-uninfected population. BCG
vaccination in infancy has approximately 59% efficacy against
childhood pulmonary TB (Mangtani et al., 2014), but offers
90% protection against severe childhood disease phenotypes
such as miliary and meningitic TB (Mangtani et al., 2014),
which are largely responsible for the high TB mortality in
this age group. The possibility that infant BCG vaccination
also confers non-specific benefits, including reduction in early
all-cause mortality, remains controversial (Aaby et al., 2011;
Fine et al., 2012). The efficacy of infant BCG vaccination
against childhood TB, demonstrated in many observational
studies and randomized trials since BCG was first used in
1921, has resulted in universal infant BCG vaccination being
implemented in TB endemic countries (Zwerling et al., 2011).
However, despite almost 100 years of experience with this
vaccine, several challenges have limited the impact of BCG
vaccination policy on the global epidemic. Meta-analysis has
shown that BCG vaccination of infants (Relative risk, RR 0.41)
and TST-negative children (RR 0.26) offers significant benefit
(Mangtani et al., 2014), but BCG vaccination of TST-positive
children and older adults is least efficacious (Mangtani et al.,
2014). The impact of infant BCG vaccination on pulmonary
disease in adolescence and adults, which is responsible for
driving the cycle of Mtb transmission in high TB incidence
countries, is reduced by the fact that efficacy of infant BCG
vaccination is not durable into adulthood (Sterne et al., 1998).
Systematic reviews illustrate that, except for a handful of studies
in low TB burden settings (Aronson et al., 2004; Barreto et al.,
2005; Mangtani et al., 2018), BCG-induced protection wanes to
zero by 10–15 years after vaccination (Abubakar et al., 2013;
Sterne et al., 1998).
Bacille Calmette Guerin vaccine also has an unfavorable
risk profile in people with immune-suppressive conditions, for
example congenital immunodeficiencies or HIV infection, due to
the BCG bacteremia that follows vaccination even in immune-
competent individuals (Trevenen and Pagtakhan, 1982). Severely
immune-compromised HIV-infected infants who receive BCG at
birth are at risk of developing local, regional and disseminated
complications of BCG disease, with incidence up to 992 per
100,000 vaccinated infants and high risk of associated mortality
(Hesseling et al., 2009). Recently updated WHO guidelines
make provision for BCG vaccination to be considered for HIV-
infected children who have been established on antiretroviral
therapy, which reduces this risk significantly after immune
reconstitution (World Health Organizataion [WHO], 2018a).
Future acquisition of HIV infection in adulthood is also a
potential safety risk, due to the possibility of reactivation BCG
disease (Talbot et al., 1997), but compared to the alternative risk
of TB disease the balance of benefit would appear in favor of BCG
vaccination in high TB incidence countries.
The limitations of BCG vaccination have encouraged
development of novel vaccines designed to boost the BCG-
induced immune response and provide additional protection
against childhood TB in BCG-primed infants; and novel
vaccines designed as a safer and/or more efficacious alternative
to replace BCG vaccination in infants. The viral-vectored
candidate vaccine MVA85A, a modified Vaccinia Ankara
virus expressing antigen 85A, was the first new TB vaccine to
enter infant efficacy trials in almost 50 years (Tameris et al.,
2013). However, MVA85A boost vaccination of South African
infants did not offer additional protection against childhood
TB beyond that provided by newborn BCG vaccine, with
TB incidence 1,150 per 100,000 in MVA85A recipients vs.
1,390 per 100,000 in controls (Tameris et al., 2013). Two live
mycobacterial vaccines intended to replace BCG have also
advanced to infant trials in TB endemic countries. VPM1002
is a recombinant urease-deficient BCG expressing listeriolysin,
which was designed to be safer and more efficacious than
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BCG (Nieuwenhuizen et al., 2017). VPM1002 showed an
acceptable safety profile in infants and adults in a TB endemic
country (Grode et al., 2005); and a safety and immunogenicity
trial (NCT02391415) among 416 infants of mothers with and
without HIV infection has recently been completed. A larger
proof of concept prevention of Mtb infection (POI) efficacy
trial is planned to test whether VPM1002 vaccination of
newborn infants reduces the risk of subsequent Mtb infection
determined by IGRA conversion, compared to standard of care
BCG vaccination.
MTBVAC is a live, attenuated clinical strain of Mtb with
two independent stable deletions in the virulence genes phoP
and fadD26 (Walker et al., 2010). MTBVAC has a similar
protein, lipid, and carbohydrate antigen repertoire to virulent
Mtb, excluding those antigens regulated by phoP and coded
by fadD26; and also contains all the Mtb genes that are in
BCG vaccine, plus the M. bovis genes that have been deleted
from BCG (Arbues et al., 2013; Aguilo et al., 2017). MTBVAC
has been tested in an age de-escalation clinical development
program among BCG-naïve Swiss adults (Spertini et al., 2015);
previously BCG-vaccinated South African adults (Tameris et al.,
2019); and recently in BCG-naïve South African infants (Tameris
et al., 2019). MTBVAC showed acceptable reactogenicity, induced
a durable CD4 T cell response in infants that exceeded that
of an equivalent dose of BCG, and demonstrated dose-related
IGRA conversion and reversion (Tameris et al., 2019). The
encouraging evidence of immunogenicity supports progression
of MTBVAC into larger safety and efficacy trials, but also
confounds interpretation of tests for Mtb infection, highlighting
the need for stringent TB disease endpoint definition. MTBVAC
is currently being tested in a larger dose-defining safety and
immunogenicity trial (NCT03536117) in preparation for a safety
and efficacy prevention of disease (POD) trial in infants.
Planning for infant efficacy trials of live mycobacterial
vaccines such as VPM1002 and MTBVAC will be informed by
our understanding of infant BCG vaccination as the classical
pre-exposure approach. It appears that BCG-mediated protection
against TB acts through two component mechanisms: prevention
of Mtb infection (POI) and prevention of progression to
TB disease (POD) (Roy et al., 2014). Meta-analysis of BCG-
vaccinated IGRA-negative children followed for TB disease in 6
studies estimated that overall BCG vaccine efficacy (71%) was the
combined result of 27% efficacy against Mtb infection defined
by IGRA conversion; and 58% efficacy against progression
to TB disease in those children who did become infected
(Roy et al., 2014).
Planning for the implementation of novel infant vaccines will
also require careful consideration. It is plausible that long-lasting
protection against TB from a single infant immunization is not
possible and boost vaccination may be required to maintain
efficacy. Regular boost vaccination with high coverage may be
achievable, but the costs of this strategy to maintain the impact
on TB incidence into adolescence and adulthood would increase.
Infant vaccinees may also be more difficult to access later in
life, potentially lowering coverage; and efficacy may differ, not
least because Mtb infection prevalence increases with age. Work
is ongoing to estimate the likely effect of these factors on the
impact and cost-effectiveness of infant vaccination in different
epidemiological and health system contexts.
PRE-EXPOSURE APPROACHES TO
PREVENTION OF INFECTION (POI) IN
ADOLESCENTS
Two critical questions for new pre-exposure approaches to
vaccination of older Mtb-uninfected populations need to be
answered: (1) Can vaccination of older children and adolescents
offer additional protection against TB disease, beyond that
provided by prior infant BCG vaccination; and (2) Is that
protection durable into young adulthood, the peak age for TB
incidence? Figure 1.
Results from a recent proof-of-concept efficacy trial of
BCG revaccination provide indirect evidence relevant to
the first question (Nemes et al., 2018a). The POI trial
NCT02075203 enrolled 990 previously BCG-vaccinated, HIV-
negative, IGRA-negative, otherwise healthy, South African
adolescents. Participants were randomized 1:1:1 to receive either
BCG revaccination, the protein-subunit candidate vaccine H4
adjuvanted with IC31, or placebo, and were followed 6-monthly
for IGRA conversion over 2 years. Neither BCG revaccination
nor H4:IC31 protected against the primary endpoint of initial
IGRA conversion (Nemes et al., 2018a). However, BCG
revaccination showed statistically significant 45% efficacy [95%
confidence interval (CI) 6–68%] against the secondary endpoint,
IGRA conversion sustained through 3 and 6 months; the efficacy
estimate for H4:IC31 (30%) against the same secondary endpoint
was not statistically significant (Nemes et al., 2018a). The
reduction in sustained IGRA conversion associated with BCG
vaccination was a direct consequence of IGRA test reversion
(i.e., change from positive to negative), which occurred nearly
twice as often (46% vs. 24%) in BCG recipients compared
to placebo recipients. Clinical relevance of the POI efficacy
signal is suggested by similar 45% efficacy of BCG revaccination
against the exploratory endpoint, IGRA conversion >4.0 IU/mL
interferon-gamma (Nemes et al., 2018a). IGRA conversion to
above the 4.0 IU/mL threshold was associated with much higher
risk of progression to TB disease in two diverse populations,
i.e., South African infants (40-fold) (Andrews et al., 2017), and
Norwegian adults (30-fold) (Winje et al., 2018), compared to
those who remained IGRA-negative.
These encouraging proof-of-concept POI results suggest that
pre-exposure BCG revaccination of adolescents can protect
against sustained Mtb infection. A larger POI trial of BCG
revaccination is planned in South Africa to confirm these findings
in an expanded study population, including younger children,
at additional sites. The BCG REVAX trial will aim to replicate
the efficacy signal against sustained Mtb infection with greater
precision; assess durability of protection through 4 years after
vaccination; and discover and validate immune correlates of
vaccine-mediated protection. However, in order to inform policy
recommendations for BCG revaccination, the significance of
efficacy against POI endpoints (sustained IGRA conversion and
conversion >4.0 IU/mL) should be confirmed in trials that test
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efficacy of vaccination of IGRA-negative populations against
progression to TB disease Figure 1.
Two novel vaccine candidates are also being tested for POI
efficacy in adolescent and adult populations. Proof of concept
POI efficacy trials can be significantly smaller, shorter and
cheaper than similar POD trials (Nemes et al., 2019), since
IGRA conversion endpoints accrue at rates more than 10-
fold that of TB disease in endemic settings where the force
of Mtb infection is high (Nemes et al., 2018a). A positive
efficacy signal from a POI trial would support advancement of a
candidate vaccine into larger and more expensive POD efficacy
trials, but this experimental medicine approach to candidate
vaccine development is not without drawbacks. First, it is
conceivable that those individuals protected against sustained
Mtb infection by a vaccine might form part of the 85–90% of
infected people who would control that infection by natural
immunity and would never progress to TB disease, even in
the absence of vaccination (Ellis et al., 2015). In this case,
a positive POI efficacy signal might not translate into POD
efficacy. Second, it is equally conceivable that a vaccine that
would protect against progression to TB disease might not show
efficacy against Mtb infection, which occurs by very different
pathological mechanisms. In that case, a negative POI efficacy
signal might hinder or even halt further development of a
potentially efficacious POD vaccine (Nemes et al., 2019). Third,
recent studies suggest that heavily Mtb-exposed individuals with
negative IGRA or TST have interferon-gamma-independent T
and B cell responses to Mtb-specific antigens (ESAT6/CFP10) (Lu
et al., 2019). These data indicate that IGRA and TST endpoints
do not capture the full spectrum of Mtb-infected individuals,
since the presence of these responses suggests previous or current
infection with Mtb. The implication for POI trials based only on
the IGRA endpoint is that since interferon-gamma-independent
conversion and reversion events would not be captured, the true
extent of vaccine-induced protection against Mtb infection might
be over- or under-estimated. The significance of interferon-
gamma-independent T and B cell responses to Mtb-specific
antigens for interpretation of clinical trial endpoints may yet
become clear from analysis of the planned BCG REVAX trial,
and ongoing studies to discover immune correlates of vaccine-
mediated protection against Mtb infection (Nemes et al., 2018b)
and TB disease (Van Der Meeren et al., 2018).
DAR-901 is an inactivated whole-cell M. obuense candidate
TB vaccine (von Reyn et al., 2017), which is related to a
first-generation multi-dose preparation originally thought to
be M. vaccae that was shown to have 39% efficacy against
bacteriologically confirmed pulmonary TB in previously BCG-
vaccinated, HIV-infected Tanzanian adults (von Reyn et al.,
2010). DAR-901 is being tested in a POI efficacy trial
(NCT02712424) of a three-dose regimen among 650 IGRA-
negative Tanzanian adolescents followed for IGRA conversion
over 24 months. ID93 + GLA/SE is a polyprotein comprised
of the four M. tuberculosis antigens Rv1813c, Rv2608, Rv3619c
and Rv3620c, formulated with GLA-SE adjuvant, a synthetic toll-
like receptor 4 agonist in a stable oil-in-water emulsion (Penn-
Nicholson et al., 2018). ID93 + GLA/SE is being tested in a
safety and immunogenicity trial (NCT03806686) of a three-dose
regimen among 107 previously BCG-vaccinated, IGRA-negative
Korean healthcare workers followed for 14 months for IGRA
conversion. The results of these trials will inform the design of
future POI approaches and improve our understanding of the
role of such trials in the development of new candidates.
PRE-EXPOSURE APPROACHES TO
PREVENTION OF DISEASE (POD) IN
ADOLESCENTS
A key question for TB vaccine stakeholders is whether efficacy
of BCG revaccination against sustained Mtb infection (Nemes
et al., 2018a), like that observed for primary BCG vaccination,
is similarly associated with protection against TB disease in
those individuals who do become infected (Ellis et al., 2015).
This pivotal question could be answered by a standalone POD
trial, or inclusion of a BCG revaccination arm in any POD
vaccine efficacy trial that includes IGRA-negative individuals.
Such a trial would be large and costly, given that TB incidence
rates in IGRA-negative people are approximately one-third that
of IGRA-positives (Mahomed et al., 2011a), but this important
question could be answered definitively. Funder enthusiasm
might be tempered by two large randomized controlled trials
that previously tested efficacy of BCG revaccination in Brazil
(Rodrigues et al., 2005) and Malawi (Fine and Ponnighaus,
1988) and found no overall reduction in risk of TB disease,
but there are important methodological differences to be
considered. First, neither trial screened for Mtb infection before
vaccination, or tested for acquisition of Mtb infection thereafter,
so it is not possible to stratify the results by baseline IGRA
status or to evaluate POI efficacy. Second, an earlier trial of
primary BCG vaccination at the same Malawi site also did
not demonstrate efficacy (Ponnighaus et al., 1992), which raises
the possibility that prior mycobacterial exposure might have
abolished any potential benefit of BCG in this setting (Black
et al., 2002), although the extent to which BCG efficacy is
reduced through masking/blocking by prior Mtb infection as
compared to non-tuberculous mycobacterial (NTM) exposure
has not yet been delineated (Black et al., 2002; Shah et al., 2019).
Third, BCG revaccination did show 33% efficacy (95% CI 3–
54%) against TB disease in a subgroup of the Brazilian trial
among children <11 years of age at the Salvador site (Barreto
et al., 2011), a finding that is consistent with protective benefit
among younger children with lower prevalence of Mtb infection
(and/or NTM exposure) at the time of vaccination. Although
some countries previously practised BCG revaccination it has
been discontinued from many immunization programs in the
context of declining national TB epidemics (Leung et al.,
2001). By contrast, the need to discover new vaccines or
repurpose old vaccines to prevent TB in the developing countries
of Asia and Sub-Saharan Africa remains urgent. Safety and
immunogenicity of the live attenuated M. tuberculosis candidate
vaccine MTBVAC is also being tested in a dose-defining
trial (NCT02933281) among IGRA-negative and IGRA-positive
South African adults, in preparation for a future pre-exposure
POD efficacy trial.
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Funding for a pre-exposure efficacy trial of BCG
revaccination, VPM1002 or MTBVAC among IGRA-negative
adolescents and young adults would compete for limited
resources against other candidate TB vaccines and alternative
approaches. It remains to be seen whether pre-exposure
vaccination of IGRA-negative children and adolescents can
provide durable protection against subsequent Mtb infection
and TB disease that lasts into adulthood, a factor that would
be crucial for impact on the epidemic in high TB transmission
settings. The alternative approach, post-exposure vaccination
of IGRA-positive individuals, could be tested in shorter, smaller
and less costly trials, since TB case endpoints would accrue
approximately threefold faster than among IGRA-negatives
(Mahomed et al., 2011a).
POST-EXPOSURE APPROACHES TO
PREVENTION OF DISEASE (POD) IN
ADULTS
The primary results of a randomized, double-blind, placebo-
controlled efficacy trial (NCT01755598) of the candidate protein-
subunit vaccine M72/AS01E for prevention of TB disease in
individuals who were IGRA-positive at the time of vaccination
were recently published (Van Der Meeren et al., 2018). M72 is a
fusion protein of two immunogenic Mtb antigens (Mtb32A and
Mtb39A) combined with AS01 adjuvant. The trial enrolled 3,573
healthy IGRA-positive, HIV-negative adults aged 18–50 years
of age in South Africa, Kenya, and Zambia; most participants
(70%) were known to have received prior BCG vaccination.
Participants received two injections of either M72/AS01E or
placebo 1 month apart and were followed for symptomatic TB
disease for up to 3 years. Ten participants in the M72/AS01E
arm and 22 participants in the placebo arm met the primary
case definition for bacteriologically confirmed pulmonary TB
diagnosed before start of treatment, after mean follow-up of
2.3 years, giving incidence rates of 0.3 and 0.6 cases per 100
person years, respectively. Efficacy of M72/AS01E vaccination
was 54% (95% CI 3 – 78) against progression to TB disease in
this Mtb-infected (IGRA-positive) population (Van Der Meeren
et al., 2018). Final results of this trial after 3 years of follow-up
showed that incidence rates were unchanged, with 13 cases in the
vaccine arm and 26 cases in the placebo arm, giving 50% vaccine
efficacy (95% CI 2 – 74) (Tait et al., 2019).
The results of the efficacy trial of M72/AS01E are a landmark
for TB vaccine development. This is the first positive efficacy
signal for an adjuvanted protein-subunit candidate TB vaccine
in Mtb-infected individuals, a population for whom BCG
is thought to offer little or no protection (Mangtani et al.,
2014). The next steps for development of M72/AS01E and fast-
follower protein-subunit vaccines will be determined by the gaps
in our understanding of the public health impact and cost-
effectiveness of implementation in different populations and
geographic settings. These encouraging results in an IGRA-
positive population would need to be confirmed with greater
precision in a larger Phase 3 trial that includes a wider age
range and sites representative of other epidemiological settings,
whilst recognizing that inclusion of populations with lower TB
incidence would add to the size and cost of any licensure trial.
Perhaps the most critical knowledge gap is the lack of efficacy
data for individuals who are IGRA-negative at the time of
vaccination Figure 1. M72/AS01E induces a higher M72-specific
CD4 T cell response in IGRA-positive compared to IGRA-
negative adolescents and adults (Day et al., 2013; Penn-Nicholson
et al., 2015). Since Phase 2 studies previously demonstrated
safety in IGRA-negative persons (Day et al., 2013; Penn-
Nicholson et al., 2015), implementation of an M72/AS01E mass
vaccination campaign would not need pre-vaccination IGRA
testing for safety reasons. However, from the health economics
perspective, calculating the cost-effectiveness of community-
wide M72/AS01E vaccination may hinge on estimates of efficacy
in both the Mtb-infected and Mtb-uninfected populations. It
is not known whether a two-dose M72/AS01E vaccination
regimen offers the same level of protection to IGRA-negative and
IGRA-positive individuals; whether priming by Mtb infection
is a necessary component of the M72/AS01E vaccine-induced
protection observed in IGRA-positive people; and if so, whether
adolescent BCG revaccination could fulfill that priming function
prior to M72/AS01E vaccination of IGRA-negative adults. The
issue of efficacy in IGRA-negative individuals is particularly
crucial for age-targeted vaccination of children and adolescents,
who have lower prevalence rates of Mtb infection than adults
(Mahomed et al., 2006, 2011b), and for mass campaigns in
countries such as Kenya (Nduba et al., 2019), Uganda (Mumpe-
Mwanja et al., 2015), and China (Gao et al., 2015), where the
majority of the adult population is Mtb-uninfected. Efficacy
data for pre-exposure vaccination of IGRA-negative populations
will likely be crucial to motivate the health system use case,
even in high TB burden countries, and any Phase 3 trial
should be adequately powered to provide a definitive answer
to this question.
The impact of vaccines that are efficacious in pre-
exposure versus post-exposure approaches will be influenced
by epidemiological setting and vaccine implementation.
Determinants of impact include the relative contribution to TB
disease burden from recent Mtb transmission versus reactivation,
and the prevalence of Mtb infection in the vaccinated population,
in particular when considering age-targeted vaccination of
children or adolescents in whom Mtb infection prevalence is
lower than in adult populations (Harris and White, 2018; Harris
et al., 2019; Renardy and Kirschner, 2019). Modeling the impact
and cost-effectiveness of M72/AS01E vaccination would be
the first step when considering feasibility and cost of roll-out.
Country-specific models could inform public health stakeholders
of the effect of varying the assumptions for efficacy in both
the IGRA-negative and IGRA-positive population, efficacy in
HIV-infected persons, age of routine vaccination, and the speed
and coverage of mass campaigns.
Development of several fast-follower candidate TB vaccines
in the clinical pipeline is likely to be accelerated by the positive
M72/AS01E findings. Protein-subunit vaccines designed for
post-exposure approaches include ID93 + GLA/SE; H56:IC31,
a fusion protein of the three mycobacterial antigens Ag85B,
ESAT-6, and Rv2660c formulated in IC31 adjuvant, which has
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been dose-optimized for both IGRA-negative and IGRA-positive
populations with prior BCG vaccination (Suliman et al., 2018a);
and GamTBvac, which consists of a fusion protein of antigens
Ag85A, ESAT6 and CFP10 with a dextran-based adjuvant
(Tkachuk et al., 2017). Safety and immunogenicity of GamTBvac
is being tested in 180 IGRA-negative, previously BCG-vaccinated
Russian adults (NCT03878004). Other viral-vectored vaccine
candidates in early stage trials include Ad5Ag85A, a serotype-5
adenovirus expressing Ag85A (Jeyanathan et al., 2016), which
is being evaluated for intramuscular or aerosol administration
(NCT02337270); and TB/FLU-04L, a live-attenuated influenza-A
that expresses antigens Ag85A and ESAT-6, which has been
evaluated by the intranasal route in IGRA-negative, previously
BCG-vaccinated adults (NCT02501421). An inactivated
preparation of M. vaccae, originally developed for therapeutic
use (Yang et al., 2011), has also been tested in a large randomized
controlled preventive efficacy trial (NCT01979900) of a six-dose,
2-weekly schedule among 10,000 Chinese adults with strongly
positive TST (>15 mm diameter) followed for incident TB
disease for at least 2 years; the trial, which ended in 2017, is yet to
publish results.
PREVENTION OF DISEASE IN
HIGH-RISK POPULATIONS
Household and Close Contacts
Alternative TB vaccination approaches targeted at high-risk
populations, including those with higher IGRA-positive
prevalence rates than in surrounding communities, might
also be considered for testing in future trials. Vaccination of
household or close contacts of a patient with TB is a potential use
case for any vaccine that offers protection against progression
from Mtb infection to TB disease (Van Der Meeren et al.,
2018). Developed, low TB burden countries with established
contact-tracing, screening and chemoprophylaxis programs
are able to identify IGRA-positive contacts who are offered TB
preventive therapy as standard of care (Getahun et al., 2015).
New WHO guidelines now recommend that TB preventive
therapy should be considered for all close contacts in high
TB burden countries, regardless of age or HIV status (World
Health Organizataion [WHO], 2018b). The conditional WHO
recommendation does not require IGRA testing due to cost and
feasibility considerations, since prevalence of IGRA-positivity
among close contacts is high (World Health Organizataion
[WHO], 2018b). For example, although overall Mtb infection
prevalence in the South-East Asia region is estimated at 28%
(Cohen et al., 2019), as determined by TST, a study of adult
household contacts in India reported 78% prevalence (Dolla
et al., 2019). A case could be made for post-exposure vaccination
to prevent TB disease among household contacts, but several
considerations temper enthusiasm for this approach. First,
the observed 50% efficacy of M72/AS01E does not improve
on standard of care isoniazid preventive therapy (IPT) (Van
Der Meeren et al., 2018), which is estimated to be at least 60%
protective (Zenner et al., 2017), and up to 90% protective in
fully adherent patients (American Thoracic Society [ATS] and
the Centers for Disease Control and Prevention [CDC], 2000).
Second, new 1-month and 3-month rifapentine-containing
TB preventive therapy regimens with equivalent efficacy
(Sterling et al., 2016; Swindells et al., 2019) are increasingly
competitive in terms of operational feasibility and patient
acceptability, compared to a two-dose vaccination regimen
(Van Der Meeren et al., 2018). Third, any theoretical benefit of
more durable protection being offered by vaccination compared
to TB preventive therapy would depend on reinfection risk
and might not be as beneficial in low transmission settings
(World Health Organizataion [WHO], 2018b).
Conducting POD efficacy trials of new TB vaccines among
household and close contacts may be an attractive solution
to the need for diverse country and population inclusion for
licensure purposes. For example, although the total burden of
TB cases in populous countries like India and China is large
(World Health Organizataion [WHO], 2018c), the relatively
modest per person TB incidence would make community-based
TB vaccine efficacy trials prohibitively large, long, and expensive.
By contrast, trials conducted among groups with higher TB
incidence, including IGRA-positive or TST-positive persons, or
those with known exposure to an infectious TB patient, would
allow efficacy trials to be conducted in settings with low rates of
community-level Mtb transmission. This consideration applies
particularly to vaccine candidates designed for post-exposure
approaches in adults (Van Der Meeren et al., 2018), since pre-
existing mycobacterial immunity in household contacts might
present a challenge for BCG and other live mycobacterial vaccines
(Mangtani et al., 2014).
HIV Infection
HIV-infected persons are at higher risk of progression to TB
disease after infection than HIV-uninfected persons (Scriba et al.,
2016). Modeling suggests that in South Africa, a high HIV-
prevalence setting, the potential population-level impact of a
new TB vaccine would be substantially reduced if the vaccine
were contraindicated in HIV positive populations (Harris and
White, 2018). However, although there is an urgent need for a
new effective vaccine that prevents HIV-associated TB disease,
a number of safety, immunogenicity and efficacy challenges
must be overcome. Live mycobacterial vaccines like BCG,
VPM1002, and MTBVAC have an unfavorable risk profile
for persons with HIV infection (Hesseling et al., 2008); and
therefore inactivated mycobacterial, viral-vectored and protein-
subunit candidate vaccines, including M72/AS01E, might be
more appropriate for vaccination of individuals with HIV and
other immune-suppressive conditions (Thacher et al., 2014;
Kumarasamy et al., 2016, 2018). Studies of vaccination of
HIV-infected individuals have reported lower induced immune
responses, compared to HIV-uninfected individuals, which
were partly restored by antiretroviral therapy (ART) (Thacher
et al., 2014; Kumarasamy et al., 2016, 2018). M72/AS01E
showed an acceptable safety profile and did not affect HIV
viral load or CD4 cell counts in HIV-infected Swiss adults,
most of whom were receiving ART (Thacher et al., 2014).
In a second trial in India, M72/AS01E vaccination was well
tolerated and induced a polyfunctional M72-specific CD4
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T-cell response that persisted through 1 year, and which was
higher in patients receiving ART compared to those who
were ART-naïve (Kumarasamy et al., 2016, 2018). However,
the crux of the problem is that the period of maximal
risk for HIV-associated TB is the period prior to immune
reconstitution, before starting ART (Lawn et al., 2009). Can
vaccination of HIV-infected persons offer protection against TB
disease? An inactivated M. obuense candidate vaccine, given
as a five-dose regimen, previously showed 39% efficacy (95%
CI 4–61) against microbiologically confirmed pulmonary TB
in previously BCG-vaccinated, HIV-infected Tanzanian adults
with CD4 cell count of at least 200 cells/µL (von Reyn
et al., 2010), which suggests that vaccination of individuals
after diagnosis with HIV infection may be effective. Another
key question is whether vaccination prior to acquisition
of HIV infection can offer durable protection against TB
that is not subverted by subsequent immune-suppression in
the period before HIV diagnosis and establishment of ART
(Nemes et al., 2018b).
Approaches to Prevention of Recurrence
and Therapeutic Vaccination
Interest in testing novel TB vaccines for therapeutic indications
is based on the potential for a vaccine to improve treatment
outcomes for both DS- and DR-TB patients (Manjelievskaia
et al., 2016); and the opportunity to test novel candidate vaccines
in relatively small Prevention of Recurrence (POR) efficacy
trials (Ellis et al., 2015). Improved treatment outcomes might
include reductions in pulmonary morbidity, TB mortality,
treatment default, treatment failure, and post-treatment
recurrence, all of which constitute therapeutic indications for
vaccination Figure 1.
Prevention of Recurrence (POR)
The timing of administration relative to the TB treatment
course directly affects the potential for vaccination to affect
specific outcomes. For example, vaccination at the end of TB
treatment, after demonstration of microbiological cure, would
only have potential to affect post-treatment outcomes. A post-
treatment POR approach would aim to reduce the rate of
subsequent recurrence, including both relapse disease in the form
of reactivation of quiescent bacilli after apparent microbiological
cure; and reinfection disease arising from a new Mtb exposure
and infection episode (Marx et al., 2014). POR trials are appealing
for demonstration of proof of concept in that the risk of a vaccine-
related safety signal, and the potential for adverse impact of
TB-related inflammation on vaccine-induced immune responses,
are likely lower than if a therapeutic vaccine was administered
during treatment. Given that recurrent TB disease occurs at a rate
several times that of primary TB disease in the same community
(Marx et al., 2014), candidate TB vaccines could be tested for
POR efficacy in a much smaller study of TB patients compared
to community-based POD efficacy trials, although it must be
acknowledged that clinical trials in TB patients are operationally
more complex than trials in healthy volunteers. A number of
proof of concept POR trials have been designed using this
approach, in the hope that a positive POR efficacy signal would
accelerate progression into larger POD efficacy trials.
Three protein-subunit candidate TB vaccines have entered
clinical trials in TB patients. ID93 + GLA-SE has been tested
(NCT02465216) for safety and immunogenicity in a two- or
three-dose regimen among 60 HIV-uninfected, South African,
drug-sensitive pulmonary TB patients, who were confirmed
sputum culture-negative upon completion of treatment, in
preparation for larger POR efficacy trials in this population.
H56:IC31 is currently being tested (NCT02711735) for safety
and efficacy in a two-dose regimen among 900 HIV-uninfected,
South African and Tanzanian TB patients, who are vaccinated
at the end of successful treatment for drug-sensitive pulmonary
TB, when sputum smear-negative, and followed for 12 months
for recurrent TB. M72/AS01E, which was shown to protect
IGRA-positive individuals against progression to TB disease
(Van Der Meeren et al., 2018), has also been tested in TB
patients (NCT01424501), but recruitment in the study ended
prematurely because of a high incidence of large injection
site redness/swelling reactions (Gillard et al., 2016). A single-
dose regimen of the live, recombinant BCG vaccine VPM1002
is also being tested in a multicentre, randomized, placebo-
controlled trial (NCT03152903) among 2,000 successfully treated
pulmonary TB patients in India, who are followed for 12 months
for recurrent TB.
Therapeutic Vaccination
Therapeutic vaccination during the course of therapy has
potential to improve in-treatment outcomes and, provided
efficacy is durable, also post-treatment outcomes including
reduced risk of recurrent TB disease (POR). However, the
possible benefits of early vaccination for pulmonary morbidity,
TB mortality, and treatment failure must be considered against
possible safety risks, including the Koch phenomenon. For
this reason, clinical trials of new therapeutic vaccines might
progress the timing of vaccination iteratively from end of
treatment toward treatment start, depending on the absence
of safety signals, pre-set stop/go immunogenicity criteria, or
demonstration of biological effects of vaccination. Potential
measures of therapeutic benefit are similar to other host-
directed therapies (HDT), and include month 2 sputum
culture conversion and proxy measures of bacillary load,
pulmonary function tests, and PET/CT extent of lung disease
(Wallis and Hafner, 2015). Although the therapeutic goals of
vaccination might be similar to those of HDT, the desired
immunologic outcomes of therapeutic vaccination might differ
from vaccination for POI and POD indications. For example,
lung function and disease severity outcomes may be exacerbated
by pro-inflammatory innate or adaptive immune responses that
might be harmful for therapeutic indications, yet otherwise
beneficial for POI and POD indications.
Two inactivated mycobacterial candidate vaccines have been
tested as immunotherapeutic adjuncts to TB treatment. M.
vaccae has been tested among DS- and DR-TB patients in a
number of clinical trials in China (Yang et al., 2011; Weng
et al., 2016). Meta-analysis of 25 studies involving 2,281 Chinese
MDR-TB patients suggested that multi-dose M. vaccae during
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treatment was associated with faster sputum smear conversion
and radiographic disease resolution (Weng et al., 2016). A larger
meta-analysis of more than 4,000 DS- and DR-TB patients in 54
studies, including six conducted in countries other than China,
also reported faster sputum smear conversion and radiographic
improvement in M. vaccae recipients (Yang et al., 2011). These
encouraging data require confirmation in other populations
and epidemic settings. A multi-dose regimen of heat-killed M.
indicus pranii (MIP), previously known as Mycobacterium w,
has also been tested for therapeutic potential among 890 re-
treatment pulmonary TB patients in a randomized, double-blind,
placebo-controlled trial in India (Sharma et al., 2017). MIP
vacinees showed a modest increase in the rate of sputum culture
conversion from 4 weeks onward compared to placebo (67% vs.
57%), but the rate of relapse TB disease was not significantly
different (Sharma et al., 2017).
It is important to note that if POR and/or therapeutic vaccine
efficacy were demonstrated in combination with current lengthy
standard of care TB treatment regimens for DS- or DR-TB, for
example by reducing the rate of TB treatment failure, mortality,
or recurrence, the vaccine might not be implemented with
the aim of achieving the observed reductions in unfavorable
treatment outcomes. Rather, the same vaccine might be tested
with novel drug combinations toward the ultimate goal of shorter,
simpler, and more effective TB treatment regimens.
Prevention of disease vaccines are expected to be agnostic
to Mtb drug sensitivity profile, since it is thought there is little
or no overlap between vaccine antigens and the proteins and
enzymes responsible for TB drug resistance (Manjelievskaia et al.,
2016). By contrast, since the severity and extent of TB disease
pathology and the resulting inflammatory milieu are directly
related to effectiveness of treatment (Chen et al., 2014), the
efficacy of therapeutic and POR vaccines might well be regimen-
specific, and different for DR- and DS-TB strains. Whilst clinical
trial outcomes for DR-TB have improved (Nunn et al., 2019),
historical rates of treatment default, treatment failure, and TB
mortality have far exceeded rates of post-treatment TB recurrence
(Ahuja et al., 2012), since many DR-TB patients have not survived
to cure (Ahuja et al., 2012; Aung et al., 2014). The inactivated
mycobacterial vaccine candidate RUTI (Nell et al., 2014), a
liposomal formulation of fragmented M. tuberculosis, is planned
to enter a double-blind, placebo-controlled trial of safety and
immunogenicity in 27 DR-TB patients after 12 or 16 weeks
of successful intensive phase treatment (NCT02711735). By
contrast, the pattern of unfavorable treatment outcome for DS-
TB is reversed compared to DR-TB, with rates of recurrent TB
disease exceeding rates of treatment failure (Gillespie et al., 2014;
Jindani et al., 2014; Merle et al., 2014). Thus the potential public
health impact of a therapeutic vaccine would appear maximal for
DR-TB, whereas impact of a POR vaccine would appear maximal
for DS-TB.
CONCLUSION
The recent results from an efficacy trial of a novel protein-subunit
vaccine, (Van Der Meeren et al., 2018) and of a repurposed
indication for licensed BCG vaccine (Nemes et al., 2018a), are
major advances for clinical development of both pre- and post-
exposure TB vaccination approaches. Two pivotal trials have
shown for the first time that both sustained Mtb infection and
progression from Mtb infection to TB disease can be prevented
by vaccination of IGRA-negative and IGRA-positive populations,
respectively (Nemes et al., 2018a; Van Der Meeren et al., 2018).
These encouraging results will stimulate funding to expand the
clinical pipeline and accelerate empirical testing of new vaccine
candidates (Voss et al., 2018), which has been limited by a
lack of market incentives to develop new vaccines for a disease
that predominantly affects the inhabitants of resource-limited
developing countries (Garcia-Basteiro et al., 2016). The recent
results also require important decisions that will shape the next
generation of clinical trials to address critical knowledge gaps
and unequivocally demonstrate the public health value of new TB
vaccination strategies for endemic countries. The size and scope
of future TB vaccine efficacy trials will require consortia of public
and private funders (Matthiessen et al., 2017), concerted political
will, and as the centenary of BCG vaccination approaches,
an urgent plan of action from the TB vaccine stakeholder
community to achieve End TB targets (Uplekar et al., 2015).
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